What did @jadesglowupjourney actually say?
Honestly, not much, at least not out loud. The transcript is just a pop culture quip with zero medical content. Everything substantive lives in the caption: a 2lb loss in week 4, muscle mass ticking up from 34.9 to 35.5, and a philosophical pivot toward accepting slower, steadier progress. She frames this as "losing fat and building muscle" simultaneously while in a calorie deficit on Mounjaro.
That is actually a more nuanced take than most weight loss content on TikTok. The caption suggests she is using a body composition tracker of some kind, not just a bathroom scale, which is worth acknowledging. Still, the claims embedded in those numbers deserve scrutiny, because the details matter a lot here.
Does the science back this up?
The 2lb weekly loss claim is consistent with clinical data, but the simultaneous fat loss and muscle gain claim is where things get complicated. The short answer: possible, but probably not what her scale is actually showing.
GLP-1 and GIP receptor agonists like tirzepatide (Mounjaro) do produce meaningful weight loss. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants losing up to 20.9% of body weight over 72 weeks, but a significant portion of that loss was lean mass, not just fat. A 2023 analysis by Wilding et al. in Diabetes Care found that roughly 25-40% of weight lost on GLP-1 medications can come from lean tissue when resistance training is absent.
The idea of building muscle in a calorie deficit is real, a phenomenon called body recomposition. It is documented, particularly in people who are newer to resistance training or returning after a break (Barakat et al., 2020, Strength and Conditioning Journal). However, a 0.6-unit increase on a consumer-grade body composition scale is almost certainly within the margin of measurement error, not a confirmed physiological gain.
What did they get wrong (or right)?
Credit where it is due: the mental reframe toward slow, steady progress is genuinely good advice and aligns with what behavioral weight loss research supports. Expecting dramatic weekly drops sets people up for disappointment and often drives them to abandon effective treatments prematurely.
What is shakier is the confident declaration of "losing fat and building muscle" based on consumer bioelectrical impedance data. BIA devices, the technology inside most smart scales and handheld trackers, have a measurement error of roughly plus or minus 3-5% for body fat percentage (Ling et al., 2011, Obesity Reviews). A 0.6-unit change in muscle mass is statistically noise on most of these devices. It does not confirm recomposition is happening.
She is not wrong that recomposition is possible on tirzepatide, especially if she is doing resistance training, which the caption does not mention. But presenting a 0.6-unit scale reading as proof of muscle building is overclaiming what the data can support.
What should you actually know?
If you are on a GLP-1 or dual GIP/GLP-1 medication and tracking body composition, a few things are worth keeping in mind. First, protein intake and resistance training are not optional if preserving muscle is the goal. Multiple studies, including Biolo et al. (1997, American Journal of Physiology) and more recent work by Cava et al. (2017, Advances in Nutrition), show that higher protein intake during caloric restriction significantly reduces lean mass loss.
Second, 2lbs per week in week 4 is a reasonable and sustainable pace. Faster early losses are often water weight and glycogen depletion, not fat. The fact that losses are normalizing at week 4 is biologically expected, not a failure.
Third, do not over-invest in week-to-week body composition readings from consumer devices. Hydration status, time of day, and recent meals all shift BIA readings significantly. Trend over months, not individual data points, is what matters.